Management of Choroidal Neovascularization in Myopic Macular Degeneration

Alfredo Pece; Vincenzo Isola; Lucia Vitale


Expert Rev Ophthalmol. 2008;3(3):311-323. 

In This Article

Expert Commentary

The field of macular degeneration research continues to experience improving therapeutic options in the management of CNV. In myopic macular degeneration, as in age-related macular degeneration, both retina specialists and, above all, the patients, face the treatment of the disease with new enthusiasm and optimism. In fact, evidence suggests that the angiogenic factor plays a significant role in the development of CNV. Therefore, the possibility of using drugs able to inhibit VEGF opens a window of hope for myopic patients, often young, with the objective to maintain visual capability enough for the daily activities such as driving, working, reading and writing.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: